Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Fisher Asset Management LLC

Fisher Asset Management LLC reduced its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 2.1% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 153,449 shares of the medical equipment provider’s stock after selling 3,348 shares during the quarter. Fisher Asset Management LLC’s holdings in Lantheus were worth $16,841,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently added to or reduced their stakes in the company. Moloney Securities Asset Management LLC purchased a new stake in shares of Lantheus during the 3rd quarter worth about $1,066,000. Hancock Whitney Corp boosted its position in Lantheus by 265.6% during the first quarter. Hancock Whitney Corp now owns 20,151 shares of the medical equipment provider’s stock worth $1,254,000 after purchasing an additional 14,639 shares in the last quarter. Wealth Enhancement Advisory Services LLC acquired a new stake in Lantheus in the second quarter valued at approximately $290,000. Van ECK Associates Corp increased its position in shares of Lantheus by 58.6% in the third quarter. Van ECK Associates Corp now owns 58,472 shares of the medical equipment provider’s stock valued at $6,469,000 after buying an additional 21,604 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA acquired a new position in shares of Lantheus during the 3rd quarter worth approximately $25,955,000. 99.06% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

LNTH has been the subject of several recent analyst reports. Redburn Atlantic started coverage on shares of Lantheus in a report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price target for the company. StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. JMP Securities lowered their price objective on Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a report on Thursday, November 7th. Finally, Truist Financial reissued a “buy” rating and set a $120.00 target price (down previously from $135.00) on shares of Lantheus in a report on Friday, November 8th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, Lantheus has a consensus rating of “Moderate Buy” and an average target price of $122.50.

Lantheus Trading Up 0.8 %

LNTH stock opened at $90.27 on Thursday. The business’s fifty day moving average price is $102.48 and its 200 day moving average price is $97.13. Lantheus Holdings, Inc. has a 12-month low of $50.20 and a 12-month high of $126.89. The company has a market capitalization of $6.28 billion, a PE ratio of 15.02 and a beta of 0.51.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.